Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

• Status: Unknown status
• Trial end date: 2017-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to analyze gene expression signature and immunohistochemical markers associated with clinical and pathological response to neoadjuvant chemotherapy in locally advanced breast cancer.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Barretos Cancer Hospital
• Collaborator: University of Sao Paulo
• Treatments: Albumin-Bound Paclitaxel; Cyclophosphamide; Doxorubicin; Liposomal doxorubicin; Paclitaxel

Criteria

Inclusion Criteria:

• Women with locally advanced women breast cancer

• Histology: ductal ou lobular invasive histology

• Agreement to take part in the study and signature of the informed consent

• Clinical condition to receive doxorubicin/cyclophosphamide and paclitaxel

• ECOG 0 or I

Exclusion Criteria:

• Not clinical stage III

• Inflammatory breast cancer

• Previous treatment

• Previous diagnosis of cancer (except basal cell or squamous cell skin carcinoma and non-invasive cervical carcinoma)

• Pregnancy

• Absence of clinical condition to receive chemotherapy